涟钢慢性稳定性心绞痛药物治疗现状及依从性调查

目的 了解华菱集团涟钢社区(简称涟钢)慢性稳定性心绞痛(SAP)中西药治疗现状,提高依从性.方法 由医师填写固定格式、内容的调查表,收集到130例已确诊并治疗至少2个月以上的慢性稳定性心绞痛门诊患者资料.以初次登记了解药物治疗现状,2个月后再次登记用药情况并对照初次登记用药情况,了解依从性.结果 用药现状:抗血小板药应用率为92.3‰、他汀类降脂药84.6％、ACEI/ARB类30.8％、β受体阻滞剂53.8％,钙拮抗剂38.5％,硝酸酯类61.5％,中成药84 6％;依从性75％～91.7％.结论 该研究的用药情况大体遵循了指南,但具改善预后的β受体阻滞剂、他汀类降脂药、ACEI/ARB应用不足,中成药使用率过高;部分药物依从性差.

Investigation of the current status and the compliance in chronic stable angina pectoris patients in Liangang

【Objective】 To understanding the Valin Group Liangang Community(hereinafter referred to Liangang) with chronic stable angina(SAP) in the western medicine treatment status,and improve compliance.【Methods】 By a physician to fill in a fixed format,the content of the questionnaire,collected 130 cases have been confirmed and the treatment of at least two or more chronic stable angina clinic patient data.Understanding of drug treatment status,as for initial registration and register again two months after drug use and control the initial registration of drug use,understanding of compliance.【Results】 Medication Status: anti-platelet drug application was 92.3%,the statin class of lipid-lowering drugs was 84.6%,30.8% of ACEI / ARB class,53.8% of β-blockers,calcium antagonists,38.5%,61.5% nitrates,proprietary Chinese medicines 84.6%;compliance of 75%～91.7%.【Conclusion】 Medication in this study generally follows the guidelines,but with β-blockers improve prognosis,statin lipid-lowering drugs,ACEI / ARB application and use of proprietary Chinese medicines;some of the drugs with poor compliance.